Published May 21, 2020
| Version v1
Journal article
Open
miRNA let-7b inhibitors by treatment of diabetic retinopathy: evaluation patent US2019093106
Creators
- 1. Dirección de Innovación y Transferencia de Conocimiento, Benemérita Universidad Autónoma de Puebla, Ciudad Universitaria, San Manuel, Puebla, México. C. P. 72570
Description
ABSTRACT
Introduction: diabetic retinopathy is a clinical complication that affects to a 93 million people suffering from diabetes and is responsible for more hospitalizations than any other complication of diabetes. Authors of US2019093106 patent propose a method for treatment of diabetic retinopathy. Areas covered: US2019093106 describes a method that consists of the administration of inhibitor of miRNA let-7b, in patients with diabetic retinopathy; additionally describe a method to inhibiting the effects of increased levels or activity of miRNA let-7b. Expert opinion: The results pre-clinical trials support the therapy’s efficacy; however, the invention is not new considering art state, whereby, new studies will be necessary to determine other administration routes, e.g. topical, dose and time of administration.
Files
3 miRNA let-7b inhibitors by treatment of diabetic retinopathy evaluation patent US2019093106.pdf
Files
(466.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:b5fb307964340f6a547efa965982f934
|
466.6 kB | Preview Download |
Additional details
Identifiers
Related works
- Is identical to
- Journal article: https://repositorioinstitucional.buap.mx/handle/20.500.12371/9407 (URL)
References
- International Diabetes Federation (IDF) Diabetes Atlas. 3rd edition. Brussels, Belgium: International al Diabetes Federation; 2017.
- International Diabetes Federation (IDF) Diabetes Atlas. 3rd edition. Brussels, Belgium: International Diabetes Federation; 2015.
- Pozo L, Bello F, Suarez A, et al. Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence. World journal of diabetes, 2019, 10(5), 291-303.
- Zhang P, Lu J, Jing Y, et al. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis. Annals of medicine, 2017,49(2), 106-16.
- Whitehead M, Wickremasinghe S, Osborne A, et al. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert opinion on biological therapy, 2018,18(12), 1257-70.
- Sloan G, Shillo P, Selvarajah D, et al. A new look at painful diabetic neuropathy. Diabetes research and clinical practice. 2018, 144:177-191.
- Kopel J, Pena-Hernandez C, Nugent K. Evolving spectrum of diabetic nephropathy. World journal of diabetes, 2019,10(5), 269.
- Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64.
- Leasher JL, Bourne RR, Flaxman SR, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39:643-9.
- Wu L, Fernandez-Loaiza P, Sauma J, et al. Classification of diabetic retinopathy and diabetic macular edema. World J Diabetes. 2013;4:290-4.
- Zhou Y, Qi C, Li S, et al. Diabetic Nephropathy Can Be Treated with Calcium Dobesilate by Alleviating the Chronic Inflammatory State and Improving Endothelial Cell Function. Cellular Physiology and Biochemistry, 2018;51(3):1119-1133.
- Graber R, Farine JC, Losa GA. Calcium Dobesilate protects human peripheral blood mononuclear cells from oxidation and apoptosis. Apoptosis, 1998;3:41-9.
- Opreanu M, Lydic TA, Reid GE, et al. Inhibition of cytokine signaling in human retinal endothelial cells through downregulation of sphingomyelinases by docosahexaenoic acid. Investigative ophthalmology & visual science, 2010;51(6):3253-63.
- Bressler SB, Liu D, Glassman AR, et al. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab. JAMA ophthalmology, 2017;135(6):558-68.
- Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. The Lancet, 2017;389(10085):2193-203.
- Stewart MW. A review of ranibizumab for the treatment of diabetic retinopathy. Ophthalmology and Therapy, 2017;6(1):33-47.
- Hutton DW, Stein JD, Bressler NM, et al. Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy: secondary analysis from a diabetic retinopathy clinical research network randomized clinical trial. JAMA ophthalmology, 2017;135(6), 576-84.
- Watanabe A, Tsuzuki A, Arai K, et al. Efficacy of intravitreal triamcinolone acetonide for diabetic macular edema after vitrectomy. Journal of Ocular Pharmacology and Therapeutics, 2016;32(1):38-43.
- Yilmaz T, Cordero-Coma M, Lavaque A, et al. Triamcinolone and intraocular sustained- release delivery systems in diabetic retinopathy. Current Pharmaceutical Biotechnology, 2011;12(3):337-46.
- Querques L, Parravano M, Sacconi R, et al. Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra-widefield fluorescein angiography: a pilot study. Acta Diabetologica, 2017;54(8): 769-773.
- Wykoff CC, Chakravarthy U, Campochiaro PA, et al. Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy.Ophthalmology, 2017;124(4):440-9.
- Dey BK, Yates P, University of Virginia. Compositions and methods for treating diabetic retinopathy. United States patent US2019093106, 2019 March 28.
- Bao MH, Feng X, Zhang YW, et al. Let-7 in cardiovascular diseases, heart development and cardiovascular differentiation from stem cells. International Journal of Molecular Sciences, 2013;14(11):23086-102.
- Liang YZ, Dong J, Zhang J, et al. Identification of neuroendocrine stress response-related circulating microRNAs as biomarkers for type 2 diabetes mellitus and insulin resistance. Frontiers in Endocrinology, 2018;9:132.
- Wang B, Jha JC, Hagiwara S, et al. Transforming growth factor-pi-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney International, 2014;85(2):352-361.
- Shen J, Kelnar K, Shelton J, et al. Compositions and method related to miRNA modulation of neovascularization or angiogenesis, United States patent US2013065951, 2013 Mar 14.
- Olson E, Rooij EV, Frost R, University of Texas. Targeting of the miR-30 family and Let- 7 family as a treatment for heart disease. Worldwide patent WO2010120969, 2010 Oct 21.
- Sallustio F, Serino G, Schena FP, Universita degli studi di Bari. Method and kit for the diagnosis of IgA nephropathy. Worldwide patent WO2012056282, 2012 May 3.